Providers

Latest News

Venetoclax duration did not have a significant impact on overall survival based on univariate analysis in patients with AML or MDS. | Image credit: Sviatlana-stock.adobe.com
Venetoclax Duration Does Not Significantly Impact OS in AML or MDS

June 18th 2025

Shorter venetoclax durations in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) yielded comparable survival outcomes in a new study, challenging treatment norms.

Center on Health Equity and Access
Health Equity & Access Weekly Roundup: June 16, 2025

June 16th 2025

FIrst Choice Center | Image credit: Alliance Defending Freedom
Supreme Court to Rule Whether Pro-Life Pregnancy Center Can Avoid Subpoena

June 16th 2025

OxyContin | Image credit: Purdue Pharma
States Accept Increased Purdue Pharma Offer of $7.4B to Settle Opioid Suits

June 16th 2025

More News

AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo